Welcome to our dedicated page for BRUKER SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bruker Corporation filings document financial results, capital returns, governance actions and proxy matters for a scientific instruments and diagnostics company.
Recent Form 8-K disclosures cover quarterly and annual operating results, outlook commentary, segment information for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, and dividends on common stock and 6.375% Mandatory Convertible Preferred Stock, Series A. The definitive proxy statement covers board elections, executive compensation, pay-versus-performance data, shareholder voting items and governance practices. Other material-event filings record board composition changes and executive transition arrangements.
Bruker Corporation files its annual report describing a global business built around four segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, focused on advanced scientific instruments and superconducting materials. The company serves life science, biopharma, materials, semiconductor, microbiology, diagnostics, and government markets with NMR, mass spectrometry, X-ray, microscopy, spatial biology, diagnostics, and superconducting technologies.
Bruker reports an aggregate market value of non‑affiliate stock of $4,251,097,535 as of June 30, 2025, with 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of February 20, 2026. Backlog was about $2,569.4 million at December 31, 2025, and the workforce totaled approximately 11,085 employees worldwide. Key risks highlighted include supply chain constraints, tariffs, reduced U.S. and Chinese research funding, geopolitical tensions, currency fluctuations, competition, and potential impairment of goodwill and other long‑lived assets.
Bruker Corporation announced board changes and a new dividend. Director Dr. Cynthia M. Friend will not stand for re-election as a Class II director when her term ends at the 2026 Annual Meeting, and her decision is stated as not due to any disagreement with the company. She will continue to serve until then.
On February 19, 2026, Jack Phillips stepped down as a Class III director and was immediately re-elected as a Class II director, with his board service deemed continuous from January 1, 2026, and his compensation and benefits unchanged. The board also declared a quarterly cash dividend of $0.05 per share on Bruker’s common stock, payable on April 7, 2026 to shareholders of record as of March 23, 2026.
FRANCIS LAURA reported acquisition or exercise transactions in this Form 4 filing.
Bruker Corporation director Laura Francis received an equity award of 4,520 shares of Common Stock in the form of restricted stock units on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027. After this grant, she holds 9,018 shares directly.
Bruker Corp director Jack Phillips reported an equity award. On February 15, 2026, he acquired 4,520 shares of Common Stock through a grant classified as a “grant, award, or other acquisition.” The footnote explains this is represented by Restricted Stock Units that will vest in a single installment on February 15, 2027, when each unit will convert into one share of Common Stock. Following this award, his directly held position is reported as 4,520 shares.
BRUKER CORP director John A. Ornell received an equity grant of 4,520 shares of Common Stock in the form of restricted stock units. The award was reported at no cash purchase price and increased his directly held stake to 39,732 shares after the transaction.
The RSUs will vest in a single installment on February 15, 2027. On that vesting date, each restricted stock unit will automatically convert into one share of Bruker common stock, aligning the director’s compensation with future company performance over the vesting period.
BRUKER CORP director William A. Linton received an equity award of 4,520 restricted stock units (RSUs). The RSUs were granted at no cash cost and relate to the company’s common stock. After this grant, he directly holds 63,243 shares of common stock.
The footnote explains that these RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Bruker common stock at that time, aligning the director’s compensation more closely with future shareholder value.
Bruker Corp director Adelene Q. Perkins received an equity award of 4,520 restricted stock units (RSUs) of Common Stock on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027, and each unit will convert into one share of Common Stock at vesting. After this grant, Perkins beneficially owns 29,144 shares of Common Stock directly.
BRUKER CORP director Richard A. Packer received an equity award covering 4,520 shares of common stock as a grant of Restricted Stock Units. The RSUs will vest in a single installment on February 15, 2027, at which time each unit will convert into one share of common stock. After this award, Packer’s directly held common stock, including this grant, is reported at 93,694 shares. The grant was recorded at a price of $0.00 per share, consistent with a stock-based compensation award rather than an open-market purchase.
BRUKER CORP director Cynthia M. Friend reported an equity award of 4,520 units tied to Common Stock. The award is structured as Restricted Stock Units (RSUs) that were granted at no cash cost on the transaction date. All 4,520 RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Common Stock at that time. Following this grant, she now directly holds 22,536 shares of Common Stock, reflecting her updated ownership position.
BRUKER CORP director Bob Rosenthal reported an equity award. He acquired 4,520 shares of Common Stock through a grant classified as a grant, award, or other acquisition at a stated price of $0.00 per share.
According to the footnote, this grant is in the form of Restricted Stock Units that will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into one share of Common Stock. After this award, Rosenthal directly holds 38,781 shares of Common Stock.